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rapamycin to inhibit both infl ammation 
and fi brosis, rapamycin and its deriva-
tives may hold promise as new additions 
to the armamentarium in our fights 
against chronic kidney fi brotic diseases.
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Tools to detect and modify sickle 
cell nephropathy
JI Scheinman1
Placement of the development of a sickle cell nephropathy in a 
time/event line is helped by better measures of glomerular filtration 
rate, tubular dysfunction, and proteinuria. Preventing or slowing the 
nephropathy can improve the outcome of this complication of the 
devastating sickle cell disease.
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A major thrust in nephrology has been 
the development of guidelines for improv-
ing global outcomes of kidney disease 
(http://www.Doqi.org). Delaying kidney 
failure is especially important when the 
risk is higher, as in diabetes mellitus and 
sickle cell disease, which carry a risk of 
serious chronic kidney disease as high as 
25%.1 Far more than in other diseases, 
when kidney failure occurs in sickle cell 
disease, the treatment chosen by patient 
and physician is likely to be dialysis, a 
functionally and economically poorer 
choice than transplantation.1
As they report in the current issue, 
Voskaridou et al.2 studied 87 subjects with 
sickle cell/β-thalassemia to learn whether 
renal damage and progressive kidney dis-
ease can be detected earlier by better meas-
ures of renal function (with cystatin-C 
levels greater than 0.96 mg per liter) and 
markers of tubular damage (with serum 
β2-microglobulin levels greater than 
1.8 mg per liter and urinary N-acetyl-
β-d-glucosaminidase levels greater than 
2 units per day), compared with creati-
nine (CR) clearance alone (less than 80 ml 
per minute per 1.73 m2) or serum CR 
alone (greater than 99 µmol per liter, or 
1.125 mg per deciliter). It is assumed that 
sickle cell/β-thalassemia, although gener-
ally a milder process than HbSS sickle cell 
disease, behaves similarly in the develop-
ment of a chronic nephropathy. This 
study helps to place the sickle cell disease 
patient into an appropriate time/event line 
(Figure 1) leading to kidney failure.
It has been clear that young sickle cell 
disease patients have a high glomerular 
fi ltration rate (GFR), which decreases 
over time in many. This loss of renal 
function may not be apparent, as CR is 
usually low. Of the 87 sickle cell/β-tha-
lassemia subjects, with an average age 
of 42.6 years, six had increased CR, 35 
had decreased CR clearance, and 28 had 
increased cystatin-C.2 Unfortunately, 
we do not know whether inhibition of 
tubular CR secretion might help correct 
the serum CR errors, nor how cystatin-C 
relates to true (iothalamate) GFR in this 
population, as they diverge in several 
contexts. If serum CR were to be used 
for GFR, sickle cell disease patients with 
diminished GFR would be erroneously 
assigned to stage 0 of kidney disease 
(http://www.Doqi.org) and be presumed 
to require attention more appropriate for 
later stages.
Beneath these errors in the estimation 
of GFR in sickle cell disease patients lie 
remarkable physiologic alterations. Nearly 
30 years ago, Statius van Eps, de Jong, and 
colleagues proposed that distinctive renal 
physiologic derangements in sickle cell 
disease might lead to a chronic glomerulo-
sclerosis, as they later summarized.3 Under 
favorable conditions, sickling causes 
vascular sludging, occlusion, and even 
infarction. In the kidney, the medullary 
area provides those conditions and, over 
time, develops a form of renal papillary 
necrosis. Although usually asymptomatic, 
renal papillary necrosis may be detectable 
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radiologically in as many as two-thirds of 
patients. It was proposed that renal papil-
lary necrosis elicits a prostaglandin (PG)-
mediated vasodilatory response that may 
explain increased GFR, proximal tubular 
hyperfunction, and proteinuria, with the 
ultimate consequence of glomerular scle-
rosis. More recent studies have fi ne-tuned 
these hypotheses, but practical measures 
have not emerged to predict and prevent 
a chronic focal segmental glomerular 
sclerotic sickle cell nephropathy.
What leads from sickling to glomeru-
lar hypertrophy, renal papillary necrosis, 
proteinuria, focal segmental glomeru-
lar sclerosis, and kidney failure? Th e PG 
response to renal sickling may not only 
serve the kidney: PGE2 also stimulates 
HbF in sickle cell blood-forming colo-
nies in vitro, which would decrease the 
tendency toward red blood cell sickling.
Features of renal papillary necrosis 
in sickle cell disease were explored in a 
bromoethylamine model of renal papil-
lary necrosis in mice and were compared 
with features of equivalent partial physi-
cal kidney ablation.4 Both models resulted 
in the same serum CR levels, similar total 
(counted) nephron numbers, similar 
(measured) superfi cial single-nephron 
GFRs, and similarly increased glomerular 
pressure. With the ablation model, blood 
pressure, urine volume, and proteinuria 
were greater. Overall kidney weight was 
increased in the renal papillary necro-
sis group, perhaps refl ecting glomerular 
hypertrophy. Hypertrophy is found in 
focal segmental glomerular sclerosis with 
disparate causes, including hyperlipidemic 
hypoinsulinemic glycogen storage dis-
ease.5 Th e hypertrophy of cyanotic con-
genital heart disease is more comparable 
to that of sickle cell disease. In sickle cell 
disease, glomerular hypertrophy appears 
to be maximal and universal6 but is 
potentially reversible.
Th e diff erences between these models 
of kidney damage should be explain-
able: Within functioning nephrons (not 
necessarily in those micropunctured 
for single-nephron GFR), renal pap-
illary necrosis may result in a higher 
GFR with an increased ultrafi ltration 
coeffi  cient (that is, more fi ltration for 
the same pressure) because of greater 
glomerular hypertrophy. Ablation, not 
selectively destroying deep nephrons, 
could allow greater pressure and result-
ing proteinuria in that deep area. Th e 
equivalent serum CR in both models, 
despite the smaller number of func-
tioning nephrons that is seen in renal 
papillary necrosis, could in part result 
from the greater CR secretion in renal 
papillary necrosis. As a human parallel, 
in patients with early sickle cell disease 
with elevated inulin clearance and nor-
mal CR, the ultrafi ltration coeffi  cient is 
increased.7 Th e ablation model may be 
infl uenced more by the eff ects of angio-
tensin, which upregulates autoregulation 
— that is, the increase in glomerular 
resistance in response to increased 
perfusion pressure. Autoregulation 
is opposed by relaxation induced by 
nitric oxide and PG. In other mod-
els, angiotensin inhibition allows the 
relaxation eff ect of PG and nitric oxide, 
allowing the glomerulus to experience 
greater perfusion, and thus increased 
GFR. In still another context, experi-
mental cirrhosis with ascites, PG is 
involved in maintaining GFR. In this 
situation, as in sickle cell disease, PG 
inhibition decreases GFR, whereas in 
normal subjects it does not aff ect GFR. 
A potentially valuable area of investiga-
tion may be the physiologic role of other 
prostanoids, such as PGI2, in glomerular 
perfusion: Th ere is evidence that a PGI2 
analogue (beraprost) allows, with partial 
nephron ablation, maintenance of GFR 
without glomerular hypertension.
Th e connection between sickling and 
the renal papillary necrosis of sickle cell 
disease would appear to be straightfor-
ward but for the elaborate endogenous 
mechanisms that appear to be impor-
tant in dealing with defective perfusion. 
A prominent example is the heat shock 
system, represented by HSP70, which 
has been increased systemically in vaso-
occlusive diseases, and locally in the renal 
medulla. HSP70 might be stimulated 
by PG, as cyclooxygenase-2 inhibition 
decreases HSP70 (in dehydrated rats), 
making the cells more susceptible to pap-
illary apoptosis.
While investigating possible ‘ischemic 
preconditioning’ (resistance to repeated 
ischemic damage) in a transgenic SS 
mouse model, Nath et al. instead found 
greater susceptibility to ischemia, with 
increased vascular congestion, an increase 
in the inflammatory marker serum 
amyloid-P component (SAP, a homologue of 
C-reactive protein in humans), and 
increased caspase-3 (evidence of an 
increased cell-death pathway).8 Th eir pre-
vious work investigated the status of oxi-
dant stress in the SS model, because of the 
exposure of the renal medulla, aft er sickling 
with hemolysis, to large amounts of heme, 
a lipophilic pro-oxidant. Th e kidney then 
responded to this oxidant stress with the 
induction of heme oxygenase. Th ese obser-
vations emphasize the susceptibility of the 
inner kidney to damage from sickling, 
which include renal papillary necrosis.
Proteinuria
Recently, the eff orts to improve outcomes 
of kidney disease have included the tar-
geting of proteinuria (http://www.Doqi.
org) as a predictor and possible prevent-
able cause of decreasing kidney function. 
Urine albumin excretion of more than 
30 mg per day in the general population 
is predictive of the risk of de novo devel-
opment of impaired GFR (less than 60) 
in 4 years.
Voskaridou et al.2 found abnormal pro-
teinuria in 30% of subjects, correlated with 
increased CR and cystatin-C (personal 
communication), as well as measures of 
tubular damage (β2-microglobulin greater 
than 1.8 mg per liter) and N-acetyl-β-d-
glucosamine. How many more of these 
subjects might have had microalbuminu-
ria (by radioimmunoassay) when as many 
as 40% of patients with sickle cell disease 
have been shown to have it? Even more 
may be detected by a high-pressure liq-
uid chromatography method that detects 
non-immunoreactive albumin fragments, 
which could refl ect early perturbed tubu-
lar protein processing.
The decrease in proteinuria shown 
by the sickle cell/β-thalassemia subjects 
in response to short-term angiotensin-
converting enzyme inhibition2 is con-
sistent with our9 and others’ findings. 
Th e same eff ect has been seen on micro-
albuminuria in sickle cell disease. In the 
current study,2 angiotensin-converting 
enzyme inhibition also lowered N-acetyl-
β-d-glucosamine, which was used as an 
indicator of tubular damage.
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Considerable experimental and 
observational data implicate the physi-
ologic changes, and the accompanying 
albuminuria and proteinuria, as facilita-
tors, if not the actual causes, of the devel-
opment of focal segmental glomerular 
sclerosis. Th e causes of microalbuminuria 
and proteinuria are still unclear and are 
beyond this discussion.
Therapy
What avenues of prevention or therapy are 
suggested by clarifi cation of the elements 
and time/event lines of development of a 
sickle nephropathy (Figure 1)?
Prevention of sickling or hemolysis, 
of course, should ideally interrupt the 
cascade at the beginning10 and is cur-
rently being explored with bone mar-
row transplantation and clinical trials of 
β-globin gene therapy (begun in β-tha-
lassemia). Th e eff ects of changing the 
balance of hemoglobins, by favoring HbF 
with hydroxyurea, have been extensively 
tested.10 Th is approach is directed toward 
providing a lesser proportion of HbS, as 
does a protocol of hypertransfusion (with 
HbAA cells). Blocking adhesion of sick-
ling cells to the endothelium would allow 
susceptible cells to leave the vulnerable 
environment before sickling and obstruc-
tion occur. Th e response of the kidney to 
medullary congestion and hypoxia may 
be modifi ed by antioxidants, prostacyclin 
analogues, and angiotensin-converting 
enzyme inhibition. If glomerular hyper-
trophy itself promotes focal segmental 
glomerular sclerosis, it may be inhibited 
by somatostatin analogues. Glomeru-
lar hypertension can be reduced by 
Average age (y) Clinical observation
Harms ↓ Helps ↑
Process
Harms ↓ Helps ↑
Modifier
Aggravates ↓ Improves ↑
Therapeutic effort  
Inhibits ↓ Improves ↑
1 Anemia ↓
Pain ↓
Sickling ↓ High HbF ↑ Hypertransfusion ↑
Hydroxyurea ↑
Chg β-globin ↑ β-globin gene Rx ↑
Incr. BbA ↑ Bone marrow transplant ↑
5 GFR ↑ SCr. ↓
Hematuria ↓
Medullary congestion ↓ Incr. adhesion ↓
High oxygen ↓
Hyperperfusion ↑ High COX-1 ↑ ACEI
 Hypertrophy-EGF ↑ Hypoxia ↓ Somatostatin analogue ↑
Papillary necrosis ↓ High NO ↑
High caspase-3 ↑
High HSP70 ↑
Incr. COX-2 ↑
 10 High CRP ↓
High HO-1 ↑
Hyperfiltration ↑ Incr. AII ↓ ACEI ARB ↑
 High PGI2 ↑ PGI2 analogue ↑
High HSP70 ↑
 15 High microalbuminuria ↔ Hyperperfusion ↓ ACEI ↑
 20 High NAG ↑ Tubular function ↓ ACEI ↑
 20 High β2-M ↑ Tubular function ↓
 30 High proteinuria ↑ Glomerular Htx ↓ ACEI ↑
 30 Nl GFR FSGS ↓
 35 Low GFR ↓
 35 Incr. Cys-C ↓
 40 Low Cr Cl ↓
 50 High Cr ↓
angiotensin-converting enzyme inhibi-
tion and angiotensin receptor blockers; 
this reduction decreases proteinuria, 
which itself may be pathogenic. Th e many 
other factors that favor the progression of 
focal segmental glomerular sclerosis in 
other contexts, such as hyperlipidemia, 
protein loading, and salt intake, can 
further be modifi ed. A comprehensive 
approach to a dangerous process in a vul-
nerable population requires identifying a 
patient’s position in the time/event line 
of the disease. Voskaridou et al.2 have 
provided another tool for this purpose.
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Is there an increased long-term 
risk of hypertension and renal 
impairment after Puumala virus-
induced nephropathy?
B Rippe1
Nephropathia epidemica (NE) is a mild form of hemorrhagic fever with 
renal syndrome, assumed to have a favorable prognosis. NE patients 
who manifested a higher glomerular filtration rate and mean systolic 
blood pressure, and more proteinuria, versus controls at 5 years 
of follow-up demonstrated no major abnormalities after 10 years. 
Antihypertensive treatment was, however, more common. Could NE 
predispose some patients to develop hypertension after all?
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Puumala (PUU) virus-induced nephro-
pathy in the form of NE occurs in north-
ern parts of Scandinavia, Finland, and 
Russia, and in parts of Central and West-
ern Europe. Th e virus is a member of the 
genus Hantavirus in the Bunyaviridae 
family, and its natural host is the bank vole 
(Clethrionomys glareolus). Over the past 
decades, hantavirus infection has attained 
an increased interest, and a review on the 
topic was recently published.1
Nephropathia epidemica (NE) is char-
acterized by sudden onset with high fever, 
headache, backache, and abdominal pain 
and transient early thrombocytopenia, not 
infrequently in conjunction with conjunc-
tival hemorrhages, palatine petechiae, and 
truncal petechial rash. Th e hemorrhages 
are accompanied by oliguria, proteinuria, 
and hematuria. Within 3 days the rash dis-
appears and the patient develops polyuria. 
Th e typical renal histopathologic lesion is 
acute tubulointerstitial nephritis. Protein-
uria is most commonly due to a loss of 
albumin, refl ecting glomerular injury, but 
concomitant tubular proteinuria refl ected 
by increasing excretion of protein HC (α1-
microglobulin) and β2-microglobulin 
indicates that tubular injury also contrib-
utes to the proteinuria. Severe courses 
of NE with acute renal failure and lethal 
outcome are very rare (<1%). Th e conva-
lescent phase usually lasts from 3 weeks 
to 3 months.
The pathophysiology of hantavirus 
infection derives from the virus’ replica-
tion in macrophages and vascular endo-
thelial cells, especially those in the lung 
and in the kidney, resulting in severely 
increased endothelial permeability. Th e 
main structural protein of the virus is 
the nucleocapsid protein. For pathogenic 
hantaviruses, the entry into host cells 
occurs by attachment to αvβ3 integrin 
on the cellular surface and subsequent 
endocytosis, whereby nucleocapsids are 
released into the cytoplasm. Crucial in the 
pathophysiology of hantavirus infection 
is the increased endothelial permeability 
induced by various cytokines/chemokines 
(tumor necrosis factor-α, interferon-γ, 
interleukin-6, and others). Also, the inter-
action with αvβ3 integrin molecules seems 
to result in defective endothelial perme-
ability regulation.2
Th e long-term prognosis of NE is usu-
ally considered favorable. A series of 
46 patients in Tampere, who had gone 
through NE 3–7 years previously, mani-
fested a higher glomerular fi ltration rate 
and fi ltration fraction, more proteinuria, 
and a higher mean ambulatory systolic 
blood pressure as compared with 38 
healthy seronegative control subjects.3 In a 
study conducted aft er the Korean War, two 
of 13 patients with previous hemorrhagic 
fever with renal syndrome had hyperten-
sive vascular disease.4 Furthermore, in a 
large epidemiological survey from Balti-
more, there was an association between a 
previous infection with rat-borne Seoul-
like hantavirus and an increased risk of 
hypertensive renal disease.5 By contrast, 
a Swedish study did not demonstrate 
any differences in office blood pres-
sure between 110 PUU virus antibody-
positive and 682 antibody-negative indi-
viduals.6 However, in this material there 
was a signifi cant correlation between PUU 
antibody positivity and hypertension in 
individuals older than 60 years of age.
A 10-year follow-up study of the Tam-
pere material3 represents the hitherto 
largest prospective clinical follow-up trial 
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